As of March 2025, more than 420,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 1,200,000 patient years1
>13,000 patients in clinical trials, open-label extensions and other programmes
>408,000 patients with post-marketing experience
As of March 2025, more than 420,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 1,200,000 patient years1
>13,000 patients in clinical trials, open-label extensions and other programmes
>408,000 patients with post-marketing experience
References
1. Roche data on file: clinical trials and post-marketing data cut-off Mar 2025